Ionis Pharmaceuticals (IONS) Gross Profit (2018 - 2026)

Ionis Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $243.1 million for Q1 2026.

• In Q1 2026, Gross Profit rose 86.79% year-over-year to $243.1 million; the TTM figure through Mar 2026 stood at $590.7 million (down 16.42% YoY), while the FY2025 annual figure was $927.8 million, up 33.7% from the prior year.
• Gross Profit was $243.1 million for Q1 2026 at Ionis Pharmaceuticals, up from $195.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $321.4 million in Q4 2023 to a low of -$2.2 million in Q2 2025.
• Historically, Gross Profit has averaged $162.7 million across 5 years, with a median of $148.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Gross Profit jumped 116.89% in 2023, then plunged 100.97% in 2025.
• A 5-year view of Gross Profit shows it stood at $148.2 million in 2022, then soared by 116.89% to $321.4 million in 2023, then sank by 30.7% to $222.7 million in 2024, then declined by 12.29% to $195.4 million in 2025, then increased by 24.43% to $243.1 million in 2026.
• The last three Gross Profit figures came in at $243.1 million (Q1 2026), $195.4 million (Q4 2025), and $154.4 million (Q3 2025), per Business Quant data.